Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: Current status

Journal of Cancer Research and Therapeutics

Volumn 5, Issue 1, 2009, Pages 3-7

  Afqir, Said ^a   Ismaili, Nabil ^a,b   Errihani, Hassan ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^b NONE   (Morocco)

Author keywords

Advanced; Concurrent chemotherapy; Nasopharyngeal carcinoma; Radiotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; INTERFERON; METHOTREXATE; PACLITAXEL; UFT; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; HEAD AND NECK CANCER; HUMAN; LOW DRUG DOSE; MEDLINE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NEUTROPENIA; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NASOPHARYNGEAL NEOPLASMS; RADIOTHERAPY;

EID: 62849088578     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.48763     Document Type: Review

References (47)

1. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002;13:1007-15.
2. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 1996;77:2423-31.
3. Skinner DW, Van Hasselt CA. Nasopharyngeal carcinoma: methods of presentation. Ear Nose Throat J 1990;69:237-40.
4. Mackie AM, Epstein JB, Wu JS, Stevenson-Moore P. Nasopharyngeal carcinoma: The role of the dentist in assessment, early diagnosis and care before and after cancer therapy. Oral Oncol 2000;36:397-403.
5. Chen MS, Lin FJ, Tang SG, Leung WM, Leung W. Clinical significance of cranial nerve deficit in the therapy of nasopharyngeal carcinoma. Brit J Radiol 1989;62:739-43.
6. Cohen SG, Quinn PD. Facial trismus and myofascial pain associated with infections and malignant disease: Report of five cases. Oral Surg Oral Med Oral Pathol 1988;65:538-44.
7. Epstein JB, Jones CK. Presenting signs and symptoms of nasopharyngeal carcinoma. Oral Surg Oral Med Oral Pathol 1993;75:32-6.
8. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041-54.
9. Geara FB, Sanguineti G, Tucker SL, Garden AS, Ang KK, Morrison WH, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of distant metastasis and survival. Radiother Oncol 1997;43:53-61.
10. Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997;37:985-96.
11. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: Epidemiology, staging, and treatment. Semin Oncol 1994;21:382-97.
12. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-7.
13. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Superiority of five year survival with chemo-radiotherapy (CT-RT) vs. radiotherapy in patients (Pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: final report. Proc Am Soc Clin Oncol 2001;20:227a. [abstract 905].
14. O'Sullivan B. Nasopharynx cancer: Therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;69:S118-21.
15. Agulnik M, Epstein JB. Nasopharyngeal carcinoma: Current management, future directions and dental implications. Oral Oncol 2008;44:617-27.
16. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64:47-56.
17. Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results. J Clin Oncol 2005;23:8461-8.
18. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005;23:6966-75.
19. Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:142-51.
20. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy vs. concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-8.
21. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:1350-7.
22. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy vs. radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-7.
23. Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401-10.
24. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. J Clin Oncol 2004;22:4604-12.
25. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: Results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002;25:219-23.
26. Thephamongkhol K, Zhou J, Browman G, Wong RKW, Chan JCK, Zeng Y, et al. Chemoradiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases [abstract 5522]. Proc Am Soc Clin Oncol 2004.
27. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Final report of SQNP01: A phase III randomized trial comparing RT with chemoRT for locally advanced nasopharyngeal cancer [Abstract]. Int J Radiat Oncol Biol Phys 2006.
28. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: A factorial study. J Clin Oncol 2004;22:2643-53.
29. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-9.
30. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005;103:22-31.
31. Chan AT, Teo PM, Leung TW, Yu P, Lee WY, Leung SF, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995;33:569-77.
32. Roussy IG. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(- or - N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 1996;35:463-9.
33. Chua DT, Sham JS, Choy D, Lorvidhaya V, Sumitsawan Y, Thongpraset S, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998;83:2270-83.
34. Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 2002;94:2217-23.
35. Chan AT, Ma B, Lo YM, Leung SF, Kwan WH, Hui EP, et al. A phase II study of neoadjuvant taxol and carboplatin followed by concurrent cisplatin-radiotherapy in locoregionally advanced nasopharyngeal carcinoma with EBV DNA monitoring. J Clin Oncol 2004;22:1-8.
36. Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002;20:1845-52.
37. Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced nasopharyngeal cancer. Ann Oncol 2002;14:564-9.
38. Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, et al. A phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer 2004;100:991-8.
39. Yamouni M, Benhadji K, Lahfa I, Yekrou D, Djellali L, Brahimi M, et al. A phase II trial of docetaxel and cisplatin combination in patients with locally advanced undifferentiated carcinoma of nasopharyngeal type (UCNT) [abstract 5599]. Proc Am Soc Clin Oncol 2004;23:511.
40. Adane S, Mekki F, Bouzid K. Gemcitabine (G) plus cisplatin (C) plus radiotherapy in first-line treatment of locally advanced and metastatic undifferentiated carcinoma of the nasopharyngeal type (UCNT): preliminary results of a phase II study [abstract 5618]. Proc Am Soc Clin Oncol 2004;23:515.
41. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704.
42. International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal carcinoma (NPC) in children and adolescents. STUDY NUMBER/EFC10339. Ongoing trial.
43. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-76.
44. Chan AT, Ma BB, Hui EP, King A, Kam M, Kwan WH, et al. Phase II study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (NPC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings 2006.
45. Chen E, Winquist E, Agulnik M. A phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). Eur J Cancer supplement 2005.
46. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70.
47. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005;105:1898-904.